ABCL635 Shows Promise for Menopausal Hot Flashes in Phase 2 Trial
A new nonhormonal treatment targeting the neurokinin 3 receptor significantly reduced the frequency and severity of menopausal hot flashes in a Phase 2 trial.
A new nonhormonal treatment targeting the neurokinin 3 receptor significantly reduced the frequency and severity of menopausal hot flashes in a Phase 2 trial.
Estrogen-containing menopausal hormone therapy (MHT) may lower blood levels of lamotrigine, potentially reducing its effectiveness in some women with bipolar disorder. What do we know about this interaction, and does the risk differ with oral, transdermal, or vaginal estrogen?